(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a New Frontiers in Prostate-Specific Membrane ...

Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and Bladder. Dr. Brendan Raizenne presented Poster 4578: Prognostic utility ...

AURKA inhibitors might enhance outcomes of metastatic prostate cancer treated with androgen receptor pathway inhibitors by intensifying androgen receptor inhibition, increasing DNA-damage-related cell ...

ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Kevin Zarrabi discussing the molecular characterization of STEAP1 and STEAP2 in advanced prostate cancer. STEAP 1 and 2 ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Rana McKay ...

ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Matthew Siskin discussing real world outcomes for patients with metastatic castration resistant prostate cancer (mCRPC) ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a prostate, testicular, and penile cancers ...

Dr. Alan Bryce presented the preliminary results from a phase II trial of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC). Late-line mCRPC patients have poor ...

The PSA progression free survival in Arm A was 2.6 months versus 2.5 months in Arm B, and radiologic progression free survival was 2.1 months and 1.9 months in arm A and B, respectively. The median ...

We know from the phase 2 TROPHY-U-01 trial that sacituzumab govitecan is an active drug, with an objective response rate of 27%, 1 in addition to a response rate of 23% in the phase 3 TROPiCS-04 trial ...

ASCO annual meeting featured a urothelial carcinoma oral abstract session and a discussant presentation by Dr. John Sfakianos discussing two abstracts, including “Circulating tumor DNA in patients ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, was host to a kidney and bladder cancers oral abstract session. Dr. Tian Zhang discussed the ...